Clinical Design

This Phase 3 study enrolls patients with metastatic pancreatic cancer who harbor a KRAS G12D mutation and administers Setidegriap in combination with the standard chemotherapy regimens mFOLFIRINOX or NALIRIFOX. Participants are randomized against a placebo control, and the primary objective is to extend overall survival. The primary endpoint is overall survival; secondary objectives include progression‑free survival, symptom delay, pharmacokinetics, and safety. Patient enrollment began on February 17, 2026, and the trial remains open for recruitment.

Target and Mechanism

Setidegriap is an investigational agent that blocks aberrant signaling of the KRAS G12D mutant protein. KRAS is a pivotal regulator of cellular growth and division, and the G12D alteration is among the most prevalent mutations in pancreatic cancer. Direct inhibition of this mutant offers a differentiated therapeutic approach relative to existing standard of care.

Differentiation from Existing Therapies

The current standard of care for metastatic pancreatic cancer consists of the chemotherapy regimens FOLFIRINOX or NALIRIFOX, which provide modest survival benefits. Setidegriap targets the KRAS G12D mutation and is expected to synergize with chemotherapy. While existing therapies are largely non‑specific cytotoxics, this candidate may improve the safety profile through mutation‑specific inhibition.

Market and Clinical Impact

KRAS G12D is present in over 30% of pancreatic cancer patients, and a successful therapy for this population could generate a market worth several hundred million dollars. If successful, Astellas would expand its oncology portfolio and strengthen its technological leadership relative to competitors. Conversely, a clinical failure could heighten skepticism toward direct KRAS inhibition strategies overall.